PetVivo enters registered direct offering of 575,011 shares at $2.32/share for ~$1.3M net proceeds

PetVivo Holdings, Inc.

Sold 575,011 common shares at $2.32 per share in a registered direct offering to accredited investors.
Estimated net proceeds of approximately $1.3 million after transaction expenses.
Net proceeds to fund commercialization of Spryng™ with OsteoCushion™ Technology and clinical trials.
Offering expected to close on January 9, 2023; no placement agent or underwriter involved.
Shares issued directly to purchasers under a prospectus supplement dated January 6, 2023.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

PetVivo Holdings, Inc. entered into Purchase Agreement with certain accredited investors valued at approximately $1.3 million (effective 2023-01-05).

Action: entry
Agreement: equity purchase
Counterparty: certain accredited investors
Value: approximately $1.3 million
Effective: 2023-01-05

Exact text from the filing

On January 5, 2023, PetVivo Holdings, Inc. (the “Company”) entered into a securities purchase agreement with certain accredited investors (the “Purchase Agreement”), pursuant to which the Company agreed to sell and issue an aggregate of 575,011 shares of its common stock (the “Registered Shares”) in a registered direct offering (the “Registered Offering”) of the Company’s common stock (the “Common Stock”) at a purchase price of $2.32 per share.

View on SEC.gov

Browse all material agreements →

PetVivo Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-000971

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.